Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915532 | 0.86 | CMA1 (0.32) | CMA1 | |
| SCHEMBL23915455 | 0.86 | SMN1; SMN2 (0.39) | NPC1CMA1 | |
| SCHEMBL23914644 | 0.85 | NPC1 (0.33) | NPC1CMA1EGFRIGF1RSRC | |
| SCHEMBL23915005 | 0.84 | NPC1 (0.36) | NPC1CMA1DGAT1EGFRIGF1R | |
| SCHEMBL23908827 | 0.83 | NPC1 (0.43) | NPC1CMA1EGFRIGF1RSRC | |
| SCHEMBL31411270 | 0.81 | NPC1 (0.35) | NPC1DGAT1 | |
| SCHEMBL23913695 | 0.75 | DGAT1 (0.36) | NPC1DGAT1 | |
| SCHEMBL31198904 | 0.74 | NPC1 (0.32) | NPC1DGAT1 | |
| SCHEMBL23915456 | 0.72 | AKR1B1 (0.38) | CMA1 | |
| SCHEMBL31411402 | 0.72 | F2RL1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | NPC1 467/4885CMA1 260/4885DGAT1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.